Palliative Radiotherapy for Lung Cancer

Görkem Türkkan; Alaattin Özen; Dirk De Ruysscher

doi:10.1007/978-3-031-22483-6_74-1

Palliative Radiotherapy for Lung Cancer

Görkem Türkkan^*
, Alaattin Özen
, Dirk De Ruysscher

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

Abstract

Lung cancer (LC) is the second most common cancer expected to be newly diagnosed in 2020 and the most leading cause of cancer deaths, in both men and women [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all LC patients, and 10–15% have small-cell lung cancer (SCLC). At diagnosis, approximately 60% of the LCs are diagnosed at stage III or IV [2].

Original language	English
Title of host publication	Airway Diseases: Volume 1-3
Editors	Cemal Cingi , Arzu Yorgancıoğlu , Nuray Bayar Muluk , Alvaro A. Cruz
Publisher	Springer
Pages	1347-1363
Number of pages	17
Volume	2
ISBN (Electronic)	9783031224836
ISBN (Print)	9783031224829
DOIs	https://doi.org/10.1007/978-3-031-22483-6_74-1
Publication status	Published - 1 Jan 2023

Access to Document

10.1007/978-3-031-22483-6_74-1

Cite this

@inbook{4b30682560bc4540976c21b6afcbccd3,

title = "Palliative Radiotherapy for Lung Cancer",

abstract = "Lung cancer (LC) is the second most common cancer expected to be newly diagnosed in 2020 and the most leading cause of cancer deaths, in both men and women [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85\% of all LC patients, and 10–15\% have small-cell lung cancer (SCLC). At diagnosis, approximately 60\% of the LCs are diagnosed at stage III or IV [2].",

author = "G{\"o}rkem T{\"u}rkkan and Alaattin {\"O}zen and \{De Ruysscher\}, Dirk",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-031-22483-6\_74-1",

language = "English",

isbn = "9783031224829",

volume = "2",

pages = "1347--1363",

editor = "\{Cemal Cingi\} and \{Arzu Yorgancıoğlu\} and \{Nuray Bayar Muluk\} and \{Alvaro A. Cruz\}",

booktitle = "Airway Diseases: Volume 1-3",

publisher = "Springer",

address = "United States",

}

TY - CHAP

T1 - Palliative Radiotherapy for Lung Cancer

AU - Türkkan, Görkem

AU - Özen, Alaattin

AU - De Ruysscher, Dirk

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Lung cancer (LC) is the second most common cancer expected to be newly diagnosed in 2020 and the most leading cause of cancer deaths, in both men and women [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all LC patients, and 10–15% have small-cell lung cancer (SCLC). At diagnosis, approximately 60% of the LCs are diagnosed at stage III or IV [2].

AB - Lung cancer (LC) is the second most common cancer expected to be newly diagnosed in 2020 and the most leading cause of cancer deaths, in both men and women [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all LC patients, and 10–15% have small-cell lung cancer (SCLC). At diagnosis, approximately 60% of the LCs are diagnosed at stage III or IV [2].

U2 - 10.1007/978-3-031-22483-6_74-1

DO - 10.1007/978-3-031-22483-6_74-1

M3 - Chapter

SN - 9783031224829

VL - 2

SP - 1347

EP - 1363

BT - Airway Diseases: Volume 1-3

A2 - , Cemal Cingi

A2 - , Arzu Yorgancıoğlu

A2 - , Nuray Bayar Muluk

A2 - , Alvaro A. Cruz

PB - Springer

ER -

Palliative Radiotherapy for Lung Cancer

Abstract

Access to Document

Fingerprint

Cite this